Patents by Inventor Stephanie Geuns-Meyer
Stephanie Geuns-Meyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9365522Abstract: The present invention relates to a novel compound having a function of inhibiting ROR? activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.Type: GrantFiled: February 27, 2015Date of Patent: June 14, 2016Assignees: AMGEN INC., TEIJIN PHARMA LIMITEDInventors: Hilary Plake Beck, Shon Keith Booker, Howard Bregman, Victor J. Cee, Nagasree Chakka, Timothy D. Cushing, Oleg Epstein, Brian M. Fox, Stephanie Geuns-Meyer, Xiaolin Hao, Kenta Hibiya, Jun Hirata, Zihao Hua, Jason Human, Shinji Kakuda, Patricia Lopez, Ryota Nakajima, Kazuhisa Okada, Steven H. Olson, Hiroyuki Oono, Lewis D. Pennington, Kosuke Sasaki, Keiko Shimada, Youngsook Shin, Ryan D. White, Ryan P. Wurz, Shuyan Yi, Xiao Mei Zheng
-
Publication number: 20150266824Abstract: The present invention relates to a novel compound having a function of inhibiting ROR? activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.Type: ApplicationFiled: February 27, 2015Publication date: September 24, 2015Inventors: Hilary Plake Beck, Shon Keith Booker, Howard Bregman, Victor J. Cee, Nagasree Chakka, Timothy D. Cushing, Oleg Epstein, Brian M. Fox, Stephanie Geuns-Meyer, Xiaolin Hao, Kenta Hibiya, Jun Kirata, Zihao Hua, Jason Human, Shinji Kakuda, Patricia Lopez, Ryota Nakajima, Kazuhisa Okada, Steven H. Olson, Hiroyuki Oono, Lewis D. Pennington, Kosuke Sasaki, Keiko Shimada, Youngsook Shin, Ryan D. White, Ryan P. Wurz, Shuyan Yi, Xiao Mei Zheng
-
Patent number: 9051311Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.Type: GrantFiled: March 7, 2013Date of Patent: June 9, 2015Assignee: AMGEN INC.Inventors: Thomas Dineen, Charles Kreiman, Matthew Weiss, Stephanie Geuns-Meyer
-
Publication number: 20150018352Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.Type: ApplicationFiled: March 7, 2013Publication date: January 15, 2015Inventors: Thomas Dineen, Charles Kreiman, Matthew Weiss, Stephanie Geuns-Meyer
-
Patent number: 8642624Abstract: Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.Type: GrantFiled: November 15, 2011Date of Patent: February 4, 2014Assignee: Amgen Inc.Inventors: Guoqing Chen, Jeffrey A. Adams, Jean E. Bemis, Shon Booker, Guolin Cai, Lucian V. DiPietro, Celia Dominguez, Daniel Elbaum, Julie Germain, Stephanie Geuns-Meyer, Michael K. Handley, Qi Huang, Joseph L. Kim, Tae-Seong Kim, Alexander S. Kiselyov, Xiaohu Ouyang, Vinod F. Patel, Leon M. Smith, Markian M. Stec, Andrew Tasker, Ning Xi, Shimin Xu, Chester Chenguang Yuan, Michael D. Croghan
-
Patent number: 8557816Abstract: The present invention relates to chemical compounds having a general formula I wherein A1-8, D?, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.Type: GrantFiled: June 9, 2011Date of Patent: October 15, 2013Assignee: Amgen Inc.Inventors: Stephanie Geuns-Meyer, Victor J. Cee, Isaac Marx, Laurie Schenkel, Ryan White
-
Publication number: 20120122847Abstract: The present invention relates to chemical compounds having a general formula I wherein A1-8, D?, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.Type: ApplicationFiled: June 9, 2011Publication date: May 17, 2012Applicant: Amgen Inc.Inventors: Victor Cee, Holly Deak, Bingfan Du, Stephanie Geuns-Meyer, Zihao Hua, Matthew Martin, Issac Marx, Hanh Nho Nguyen, Philip Olivieri, Kathleen Panter, Karina Romero, Laurie Schenkel, Ryan White
-
Publication number: 20120065185Abstract: Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.Type: ApplicationFiled: November 15, 2011Publication date: March 15, 2012Applicant: Amgen Inc.Inventors: Guoqing CHEN, Jeffrey Adams, Jean Bemis, Shon Booker, Guolin Cai, Lucian Di Pietro, Celia Dominguez, Daniel Elbaum, Julie Germain, Stephanie Geuns-Meyer, Michael Handley, Qi Huang, Joseph L. Kim, Tae-Seong Kim, Alexander Kiselyov, Xiaohu Ouyang, Vinod F. Patel, Leon M. Smith, Markian Stec, Andrew Tasker, Ning Xi, Shimin Xu, Chester Chenguang Yuan, Michael Croghan
-
Patent number: 7981891Abstract: The present invention relates to chemical compounds having a general formula I wherein A1-8, D?, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.Type: GrantFiled: June 30, 2010Date of Patent: July 19, 2011Assignee: Amgen Inc.Inventors: Holly Deak, Stephanie Geuns-Meyer, Brian L. Hodous, Zihao Hua, Mathew Martin, Hanh Nho Nguyen, Philip Olivieri, Kate Panter, Karina Romero, Laurie Schenkel, Ryan White
-
Publication number: 20100280008Abstract: The present invention relates to chemical compounds having a general formula I wherein A1-8, D?, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.Type: ApplicationFiled: June 30, 2010Publication date: November 4, 2010Applicant: Amgen Inc.Inventors: Holly Deak, Stephanie Geuns-Meyer, Brian L. Hodous, Zihao Hua, Matthew Martin, Hanh Nho Nguyen, Philip Olivieri, Kathleen Panter, Karina Romero, Laurie Schenkel, Ryan White
-
Patent number: 7776857Abstract: The present invention relates to chemical compounds having a general formula I wherein A1-8, D?, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.Type: GrantFiled: April 3, 2008Date of Patent: August 17, 2010Assignee: Amgen Inc.Inventors: Victor Cee, Holly Deak, Bingfan Du, Stephanie Geuns-Meyer, Brian L. Hodous, Zihao Hua, Matthew Martin, Isaac Marx, Hanh Nho Nguyen, Philip Olivieri, Kathleen Panter, Karina Romero, Laurie Schenkel, Ryan White
-
Publication number: 20090069297Abstract: The present invention relates to chemical compounds having a general formula I wherein A1-8, D?, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.Type: ApplicationFiled: April 3, 2008Publication date: March 12, 2009Applicant: Amgen Inc.Inventors: Victor Cee, Holly Deak, Bingfan Du, Stephanie Geuns-Meyer, Brian L. Hodous, Zihao Hua, Mathew Martin, Isaac Marx, Hanh Nho Nguyen, Philip Olivieri, Kathleen Panter, Karina Romero, Laurie Schenkel, Ryan White
-
Publication number: 20070213325Abstract: The present invention relates to chemical compounds having a general formula I wherein A, B, C1, C2, D, L1, L2 and R3-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Tie-2 and Aurora kinase enzymes thereby influencing angiogenesis and the process of cell cycle and cell proliferation, respectively, to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of various protein kinases.Type: ApplicationFiled: February 21, 2007Publication date: September 13, 2007Applicant: Amgen Inc.Inventors: Victor Cee, Holly Deak, Stephanie Geuns-Meyer, Brian Hodous, Hanh Nho Nguyen, Philip Olivieri, Vinod Patel, Karina Romero
-
Publication number: 20070185111Abstract: The present invention relates to chemical compounds having a general formula I wherein A1, A2, C1, C2, D, L1, L2, Z and R1- are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.Type: ApplicationFiled: January 18, 2007Publication date: August 9, 2007Inventors: Victor Cee, Holly Deak, Bingfan Du, Stephanie Geuns-Meyer, Brian Hodous, Hanh Nguyen, Philip Olivieri, Vinod Patel, Karina Romero, Laurie Schenkel
-
Publication number: 20070054916Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.Type: ApplicationFiled: September 30, 2005Publication date: March 8, 2007Inventors: Vinod Patel, Joseph Kim, Stephanie Geuns-Meyer, Stuart Chaffee, Victor Cee, Brian Hodous, Steven Bellon, Jean-Christophe Harmange, Philip Olivieri, Maya Thaman, Erin DiMauro, John Buchanan, David McGowan, Brian Albrecht, Holly Deak, Jean Bemis, Ryan White, Matthew Martin, Gregory Habgood, Paul Tempest, Craig Masse, William Buckner, Bradley Herberich, Russell Graceffa, Dawei Zhang, Shimin Xu, Kelvin Sham, Robert Rzasa, James Falsey, Partha Chakrabarti, Guo-Qiang Cao, Susan Tomlinson, Liping Pettus, Adrian Smith, Nick Paras, Gang Liu, Frenel DeMorin, Andrew Tasker, Anthony Reed
-
Publication number: 20070049592Abstract: The present invention relates to compounds of Formulas I and II, wherein A1, A2, B1, B2, Q, X1, X2, Y and R3 are defined herein, synthetic intermediates, and pharmaceutical compositions, comprising such compounds. The compounds and compositions are capable of modulating various protein kinase receptors such as Tie-2 and, therefore, influencing kinase related disease states and conditions. The compounds, for example, are capable of treating cancer caused by unregulated angiogenesis, and inflammation as well as other proliferative disorders.Type: ApplicationFiled: August 18, 2006Publication date: March 1, 2007Inventors: Stephanie Geuns-Meyer, Stuart Chaffee, Rebecca Johnson, Joseph Kim, Joseph Nunes, Vinod Patel
-
Publication number: 20060040956Abstract: Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: ApplicationFiled: September 23, 2005Publication date: February 23, 2006Inventors: Guoqing Chen, Jeffrey Adams, Jean Bemis, Shon Booker, Guolin Cai, Lucian Di Pietro, Celia Dominguez, Daniel Elbaum, Julie Germain, Stephanie Geuns-Meyer, Michael Handley, Qi Huang, Joseph Kim, Tae-Seong Kim, Alexander Kiselyov, Xiaohu Ouyang, Vinod Patel, Leon Smith, Markian Stec, Andrew Tasker, Ning Xi, Shimin Xu, Chester Yuan, Michael Croghan
-
Patent number: 6995162Abstract: Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: GrantFiled: January 10, 2002Date of Patent: February 7, 2006Assignee: Amgen Inc.Inventors: Guoqing Chen, Jeffrey Adams, Jean Bemis, Shon Booker, Guolin Cai, Lucian Di Pietro, Celia Dominguez, Daniel Elbaum, Julie Germain, Stephanie Geuns-Meyer, Michael Handley, Qi Huang, Joseph L. Kim, Tae-Seong Kim, Alexander Kiselyov, Xiaohu Ouyang, Vinod F. Patel, Leon M. Smith, Markian Stec, Andrew Tasker, Ning Xi, Shimin Xu, Chester Chenguang Yuan, Michael Croghan
-
Publication number: 20060009453Abstract: The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other poliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.Type: ApplicationFiled: May 9, 2005Publication date: January 12, 2006Inventors: Stephanie Geuns-Meyer, Brian Hodous, Stuart Chaffee, Paul Tempest, Philip Olivieri, Rebecca Johnson, Brian Albrecht, Vinod Patel, Victor Cee, Joseph Kim, Steven Bellon, Xiaotian Zhu, Yuan Cheng, Ning Xi, Karina Romero, Hanh Nguyen, Holly Deak
-
Publication number: 20050261313Abstract: Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: ApplicationFiled: December 15, 2004Publication date: November 24, 2005Inventors: Benny Askew, Jeffrey Adams, Shon Booker, Guoqing Chen, Lucian DiPietro, Daniel Elbaum, Julie Germain, Stephanie Geuns-Meyer, Gregory Habgood, Michael Handley, Qi Huang, Tae-Seong Kim, Aiwen Li, Nobuko Nishimura, Rana Nomak, Vinod Patel, Babak Riahi, Joseph Kim, Ning Xi, Kevin Yang, Chester Yuan